SEC Comment Letter for Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Oct 8, 2019
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Oct. 8, 2019 · CIK: 0001533040 · Accession: 0000000000-19-014409
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234032
Letter
October 8, 2019 Gerrit Dispersyn President & Chief Executive Officer Phio Pharmaceuticals Corp. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 Re:Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed October 1, 2019 File No. 333-234032 Dear Dr. Dispersyn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joseph McCann at (202) 551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
October 8, 2019
Gerrit Dispersyn
President & Chief Executive Officer
Phio Pharmaceuticals Corp.
257 Simarano Drive, Suite 101
Marlborough, MA 01752
Re:Phio Pharmaceuticals Corp.
Registration Statement on Form S-1
Filed October 1, 2019
File No. 333-234032
Dear Dr. Dispersyn:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joseph McCann at (202) 551-6262 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences